AUB ScholarWorks

Efficacy and safety of rabeprazole, amoxicillin, and gatifloxacin after treatment failure of initial Helicobacter pylori eradication

Show simple item record

dc.contributor.author Sharara A.I.
dc.contributor.author Chaar H.F.
dc.contributor.author Aoun E.
dc.contributor.author Abdul-Baki H.
dc.contributor.author Araj G.F.
dc.contributor.author Kanj S.S.
dc.contributor.editor
dc.date Aug-2006
dc.date.accessioned 2017-10-05T15:59:42Z
dc.date.available 2017-10-05T15:59:42Z
dc.date.issued 2006
dc.identifier 10.1111/j.1523-5378.2006.00416.x
dc.identifier.isbn
dc.identifier.issn 10834389
dc.identifier.uri http://hdl.handle.net/10938/19187
dc.description.abstract Objectives: To evaluate the efficacy of a 7-day regimen of gatifloxacin (400 mg daily), amoxicillin (1 g twice a day), and rabeprazole (20 mg twice a day) in the secondary eradication of Helicobacter pylori infection. Methods: Eligible patients with persistent infection following one or more conventional clarithromycin-containing triple therapies were enrolled in this open-label trial. Eradication of infection was documented by 14C-urea breath test a minimum of 4 weeks after therapy and 2 weeks off any acid suppressive therapy. Culture of H. pylori and in vitro susceptibility testing to amoxicillin, clarithromycin, and gatifloxacin was done in cases of failed eradication. Results: A total of 45 patients (22 females:23 males; mean age 44.5 ± 13 years) were enrolled. Eradication occurred in 38 patients [both per-protocol (PP) and intention-to-treat analysis: 84.4percent; 95percent CI: 74-95percent]. No significant adverse effects were reported. In vitro susceptibility testing showed no secondary resistance to gatifloxacin or amoxicillin in any of the seven nonresponders. Smoking, age, and sex were not predictors of potential eradication failure. Conclusions: A 7-day regimen of gatifloxacin, rabeprazole, and amoxicillin is effective after failed eradication therapy for H. pylori and does not appear to result in secondary resistance. This combination is simple, well tolerated, and may lead to higher compliance and lower costs. © 2006 The Authors.
dc.format.extent
dc.format.extent Pages: (231-236)
dc.language English
dc.publisher OXFORD
dc.relation.ispartof Publication Name: Helicobacter; Publication Year: 2006; Volume: 11; no. 4; Pages: (231-236);
dc.relation.ispartofseries
dc.relation.uri
dc.source Scopus
dc.subject.other
dc.title Efficacy and safety of rabeprazole, amoxicillin, and gatifloxacin after treatment failure of initial Helicobacter pylori eradication
dc.type Article
dc.contributor.affiliation Sharara, A.I., Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon
dc.contributor.affiliation Chaar, H.F., School of Pharmacy, Lebanese American University, Beirut, Lebanon
dc.contributor.affiliation Aoun, E., Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon
dc.contributor.affiliation Abdul-Baki, H., Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon
dc.contributor.affiliation Araj, G.F., Department of Pathology and Laboratory Medicine, American University of Beirut Medical Center, Beirut, Lebanon
dc.contributor.affiliation Kanj, S.S., Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon, Division of Infectious Diseases, American University of Beirut Medical Center, PO Box 11-0236-16-B, Beirut, Lebanon
dc.contributor.authorAddress Kanj, S.S.; Division of Infectious Diseases, American University of Beirut Medical Center, PO Box 11-0236-16-B, Beirut, Lebanon; email: sk11@aub.edu.lb
dc.contributor.authorCorporate University: American University of Beirut Medical Center; Faculty: Faculty of Medicine; Department: Pathology and Laboratory Medicine;
dc.contributor.authorDepartment Pathology and Laboratory Medicine
dc.contributor.authorDivision
dc.contributor.authorEmail sk11@aub.edu.lb
dc.contributor.authorFaculty Faculty of Medicine
dc.contributor.authorInitials Sharara, AI
dc.contributor.authorInitials Chaar, HF
dc.contributor.authorInitials Aoun, E
dc.contributor.authorInitials Abdul-Baki, H
dc.contributor.authorInitials Araj, GF
dc.contributor.authorInitials Kanj, SS
dc.contributor.authorOrcidID
dc.contributor.authorReprintAddress Kanj, SS (reprint author), Amer Univ Beirut, Med Ctr, Div Infect Dis, Dept Internal Med, POB 11-0236-16-B, Beirut, Lebanon.
dc.contributor.authorResearcherID
dc.contributor.authorUniversity American University of Beirut Medical Center
dc.description.cited Bauernfeind A, 1997, J ANTIMICROB CHEMOTH, V40, P639, DOI 10.1093-jac-40.5.639; Bilardi C, 2004, CLIN GASTROENTEROL H, V2, P997, DOI 10.1053-S1542-3565(04)00458-6; Bock H, 2000, J CLIN GASTROENTEROL, V31, P222, DOI 10.1097-00004836-200010000-00007; Boixeda D, 2002, ALIMENT PHARM THERAP, V16, P1457, DOI 10.1046-j.1365-2036.2002.01304.x; Branca G, 2004, INT J ANTIMICROB AG, V24, P433, DOI 10.1016-j.ijantimicag.2004.02.032; Canducci F, 2001, ALIMENT PHARM THERAP, V15, P143, DOI 10.1046-j.1365-2036.2001.00909.x; Casillas JL, 2000, ADV THER, V17, P263, DOI 10.1007-BF02850009; Cheon Jae Hee, 2005, Korean J Gastroenterol, V45, P111; Coelho LGV, 2005, ALIMENT PHARM THERAP, V21, P783, DOI 10.1111-j.1365-2036.2005.02370.x; Debets-Ossenkopp YJ, 1999, J ANTIMICROB CHEMOTH, V43, P511, DOI 10.1093-jac-43.4.511; Dore MP, 2000, DIGEST DIS SCI, V45, P68, DOI 10.1023-A:1005457226341; Fujimura S, 2004, J MED MICROBIOL, V53, P1019, DOI 10.1099-jmm.0.45642-0; Fung-Tomc J, 2000, J ANTIMICROB CHEMOTH, V45, P437, DOI 10.1093-jac-45.4.437; Gisbert JP, 2003, HELICOBACTER, V8, P90, DOI 10.1046-j.1523-5378.2003.00128.x; Gisbert JP, 1999, ALIMENT PHARM THERAP, V13, P1311; Gisbert JP, 2005, ALIMENT PHARM THERAP, V21, P1249, DOI 10.1111-j.1365-2036.2005.02465.x; Gisbert JP, 2000, ALIMENT PHARM THERAP, V14, P1319, DOI 10.1046-j.1365-2036.2000.00844.x; Gomollon F, 1999, HELICOBACTER, V4, P222, DOI 10.1046-j.1523-5378.1999.99307.x; Gradelski E, 2002, J ANTIMICROB CHEMOTH, V49, P185, DOI 10.1093-jac-49.1.185; GRASELA DM, 2000, CLIN INFECT DIS S2, V31, P51; Heep M, 2000, EUR J CLIN MICROBIOL, V19, P538, DOI 10.1007-s100960000288; Hegedus O, 2002, EUR J GASTROEN HEPAT, V14, P513, DOI 10.1097-00042737-200205000-00008; Isakov V, 2002, ALIMENT PHARM THERAP, V16, P1277, DOI 10.1046-j.1365-2036.2002.01299.x; Iwao Eiji, 2003, Journal of Infection and Chemotherapy, V9, P165; Laheij RJF, 1999, ALIMENT PHARM THERAP, V13, P857; Laine L, 2000, AM J GASTROENTEROL, V95, P3393; McMahon BJ, 2003, ANN INTERN MED, V139, P463; Megraud F, 1999, ANTIMICROB AGENTS CH, V43, P2747; Murakami K, 2003, ALIMENT PHARM THERAP, V17, P119, DOI 10.1046-j.0269-2813.2003.01401.x; Murakami K, 2002, ALIMENT PHARM THERAP, V16, P1933, DOI 10.1046-j.0269-2813.2002.01368.x; Nista EC, 2003, ALIMENT PHARM THERAP, V18, P627, DOI 10.1046-j.1365-2036.2003.01676.x; Peitz U, 2002, ALIMENT PHARM THERAP, V16, P315, DOI 10.1046-j.1365-2036.2002.01173.x; Perri F, 2003, ALIMENT PHARM THERAP, V18, P815, DOI 10.1046-j.1365-20369.2003.01755.x; Perri F, 2001, AM J GASTROENTEROL, V96, P58; Perri F, 2000, ALIMENT PHARM THERAP, V14, P311; Perri F, 2001, ALIMENT PHARM THERAP, V15, P1023, DOI 10.1046-j.1365-2036.2001.01006.x; Qasim A, 2005, ALIMENT PHARM THERAP, V21, P91, DOI 10.1111-j.1365-2036.2004.02210.x; Queiroz DMM, 2002, J CLIN GASTROENTEROL, V35, P315, DOI 10.1097-01.MCG.0000028650.86049.F1; Realdi G, 1999, HELICOBACTER, V4, P106, DOI 10.1046-j.1523-5378.1999.99002.x; Rhomberg PR, 2001, DIAGN MICR INFEC DIS, V40, P45, DOI 10.1016-S0732-8893(01)00247-4; Sharara AI, 2004, HELICOBACTER, V9, P255, DOI 10.1111-j.1083-4389.2004.00220.x; Sotoudehmanesh R, 2001, DIGESTION, V64, P222, DOI 10.1159-000048865; Togawa J, 2005, HEPATO-GASTROENTEROL, V52, P645; Toro C, 2001, Rev Esp Quimioter, V14, P172; Van der Wouden EJ, 1999, ALIMENT PHARM THERAP, V13, P297; Watanabe Y, 2003, DIGEST LIVER DIS, V35, P711, DOI 10.1016-S1590-8658(03)00432-8; Wong WM, 2003, ALIMENT PHARM THERAP, V17, P553, DOI 10.1046-j.0269-2813.2003.01459.x; Wong WM, 2002, ALIMENT PHARM THERAP, V16, P793, DOI 10.1046-j.1365-2036.2002.01223.x; Zou Jun, 2003, Zhonghua Yi Xue Za Zhi, V83, P1778; Zullo A, 2003, DIGEST LIVER DIS, V35, P232, DOI 10.1016-S1590-8658(03)00059-8
dc.description.citedCount 19
dc.description.citedTotWOSCount 18
dc.description.citedWOSCount 18
dc.format.extentCount 6
dc.identifier.articleNo
dc.identifier.coden HELIF
dc.identifier.pubmedID 16882325
dc.identifier.scopusID 33745877144
dc.identifier.url
dc.publisher.address 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
dc.relation.ispartofConference
dc.relation.ispartofConferenceCode
dc.relation.ispartofConferenceDate
dc.relation.ispartofConferenceHosting
dc.relation.ispartofConferenceLoc
dc.relation.ispartofConferenceSponsor
dc.relation.ispartofConferenceTitle
dc.relation.ispartofFundingAgency
dc.relation.ispartOfISOAbbr Helicobacter
dc.relation.ispartOfIssue 4
dc.relation.ispartOfPart
dc.relation.ispartofPubTitle Helicobacter
dc.relation.ispartofPubTitleAbbr Helicobacter
dc.relation.ispartOfSpecialIssue
dc.relation.ispartOfSuppl
dc.relation.ispartOfVolume 11
dc.source.ID WOS:000239005100003
dc.type.publication Journal
dc.subject.otherAuthKeyword Clarithromycin
dc.subject.otherAuthKeyword Fluoroquinolones
dc.subject.otherAuthKeyword Gastritis
dc.subject.otherAuthKeyword Peptic ulcer
dc.subject.otherAuthKeyword Rescue
dc.subject.otherAuthKeyword Resistance
dc.subject.otherAuthKeyword Susceptibility
dc.subject.otherChemCAS amoxicillin, 26787-78-0, 34642-77-8, 61336-70-7
dc.subject.otherChemCAS carbon 13, 14762-74-4
dc.subject.otherChemCAS clarithromycin, 81103-11-9
dc.subject.otherChemCAS gatifloxacin, 112811-59-3, 180200-66-2
dc.subject.otherChemCAS rabeprazole, 117976-89-3, 117976-90-6
dc.subject.otherChemCAS 2-Pyridinylmethylsulfinylbenzimidazoles
dc.subject.otherChemCAS Amoxicillin, 26787-78-0
dc.subject.otherChemCAS Anti-Bacterial Agents
dc.subject.otherChemCAS Bacterial Proteins
dc.subject.otherChemCAS Benzimidazoles
dc.subject.otherChemCAS Fluoroquinolones
dc.subject.otherChemCAS gatifloxacin, 112811-59-3
dc.subject.otherChemCAS Omeprazole, 73590-58-6
dc.subject.otherChemCAS rabeprazole, 117976-90-6
dc.subject.otherChemCAS Urease, EC 3.5.1.5
dc.subject.otherIndex acid
dc.subject.otherIndex amoxicillin
dc.subject.otherIndex amoximex
dc.subject.otherIndex carbon 13
dc.subject.otherIndex clarithromycin
dc.subject.otherIndex gatifloxacin
dc.subject.otherIndex rabeprazole
dc.subject.otherIndex adult
dc.subject.otherIndex age
dc.subject.otherIndex antibiotic resistance
dc.subject.otherIndex antibiotic sensitivity
dc.subject.otherIndex article
dc.subject.otherIndex bacterium culture
dc.subject.otherIndex clinical article
dc.subject.otherIndex clinical protocol
dc.subject.otherIndex clinical trial
dc.subject.otherIndex confidence interval
dc.subject.otherIndex controlled clinical trial
dc.subject.otherIndex controlled study
dc.subject.otherIndex diarrhea
dc.subject.otherIndex drug cost
dc.subject.otherIndex drug dose regimen
dc.subject.otherIndex drug efficacy
dc.subject.otherIndex drug safety
dc.subject.otherIndex drug screening
dc.subject.otherIndex drug tolerance
dc.subject.otherIndex drug treatment failure
dc.subject.otherIndex eradication therapy
dc.subject.otherIndex female
dc.subject.otherIndex headache
dc.subject.otherIndex Helicobacter infection
dc.subject.otherIndex Helicobacter pylori
dc.subject.otherIndex human
dc.subject.otherIndex infection prevention
dc.subject.otherIndex male
dc.subject.otherIndex medical documentation
dc.subject.otherIndex nausea
dc.subject.otherIndex nonhuman
dc.subject.otherIndex patient compliance
dc.subject.otherIndex prediction
dc.subject.otherIndex priority journal
dc.subject.otherIndex sex
dc.subject.otherIndex smoking
dc.subject.otherIndex urea breath test
dc.subject.otherIndex 2-Pyridinylmethylsulfinylbenzimidazoles
dc.subject.otherIndex Adult
dc.subject.otherIndex Amoxicillin
dc.subject.otherIndex Anti-Bacterial Agents
dc.subject.otherIndex Bacterial Proteins
dc.subject.otherIndex Benzimidazoles
dc.subject.otherIndex Breath Tests
dc.subject.otherIndex Drug Therapy, Combination
dc.subject.otherIndex Female
dc.subject.otherIndex Fluoroquinolones
dc.subject.otherIndex Helicobacter Infections
dc.subject.otherIndex Helicobacter pylori
dc.subject.otherIndex Humans
dc.subject.otherIndex Male
dc.subject.otherIndex Microbial Sensitivity Tests
dc.subject.otherIndex Middle Aged
dc.subject.otherIndex Omeprazole
dc.subject.otherIndex Smoking
dc.subject.otherIndex Treatment Outcome
dc.subject.otherIndex Urease
dc.subject.otherIndex Helicobacter pylori
dc.subject.otherKeywordPlus RANITIDINE BISMUTH CITRATE
dc.subject.otherKeywordPlus PRETREATMENT ANTIBIOTIC-RESISTANCE
dc.subject.otherKeywordPlus STANDARD TRIPLE THERAPIES
dc.subject.otherKeywordPlus VS. QUADRUPLE THERAPY
dc.subject.otherKeywordPlus PROTON-PUMP INHIBITOR
dc.subject.otherKeywordPlus 7-DAY RESCUE THERAPY
dc.subject.otherKeywordPlus IN-VITRO ACTIVITY
dc.subject.otherKeywordPlus 2ND-LINE TREATMENT
dc.subject.otherKeywordPlus METRONIDAZOLE RESISTANCE
dc.subject.otherKeywordPlus INFECTED PATIENTS
dc.subject.otherWOS Gastroenterology and Hepatology
dc.subject.otherWOS Microbiology


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search AUB ScholarWorks


Browse

My Account